|This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (January 2014) (Learn how and when to remove this template message)|
|Industry||Pharmaceuticals & Drugs|
|Hoshang Sinor (Chairperson), Dinesh Patel (Managing Director)|
|Revenue||48.752 ( USD in Millions )|
Themis Medicare (TML) (also called Themis Chemical) incorporated in 1969, is a manufacturer of active pharmaceutical ingredients (APIs) and formulations. It is a joint venture with Gedeon Richter Plc. of Hungary. Headquartered in Mumbai, the company has four manufacturing facilities located at Vapi (Gujarat), Hyderabad (Andhra Pradesh), and Haridwar. The company also has presence in 40 countries.
TML's research and development facility focuses on development of new chemicals, new processes for production of API and intermediates, fermentation technology and new drug delivery systems. Themis Medicare also sells its research formulations to a variety of Indian pharmaceutical companies.
Thermis Medicare manufactures APIs for therapeutic segment such as antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Products include simvastatin, lovastatin, propofol, ethambutol, dimethyl isosorbide, artesunate, lumefenterine and arteether.
In 2010, the company launched a combination of lidocaine and prilocaine in spray form branded as "Lovelong" for the treatment of premature ejaculation. The company received approval from the Drug Controller General of India to manufacture and market the product in India.